Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May 23;20(5):660-6.
doi: 10.1016/j.chembiol.2013.05.001.

iPOP Goes the World: Integrated Personalized Omics Profiling and the Road Toward Improved Health Care

Free PMC article

iPOP Goes the World: Integrated Personalized Omics Profiling and the Road Toward Improved Health Care

Jennifer Li-Pook-Than et al. Chem Biol. .
Free PMC article


The health of an individual depends upon their DNA as well as upon environmental factors (environome or exposome). It is expected that although the genome is the blueprint of an individual, its analysis with that of the other omes such as the DNA methylome, the transcriptome, proteome, and metabolome will further provide a dynamic assessment of the physiology and health state of an individual. This review will help to categorize the current progress of omics analyses and how omics integration can be used for medical research. We believe that integrative personal omics profiling (iPOP) is a stepping stone to a new road to personalized health care and may improve disease risk assessment, accuracy of diagnosis, disease monitoring, targeted treatments, and understanding the biological processes of disease states for their prevention.

Conflict of interest statement

J.L.P.T declares no conflict of interest.


Figure 1
Figure 1. Schematic representing the implementation of iPOP for personalized medicine
(A) Participant tissue sample (e.g. PBMC) is collected, while environment (incl. diet, exercise, etc.), medical history and clinical data are recorded. T1 is the first time point. (B) Selected omic analysis involved in a sample iPOP study (Chen et al., 2012). (C) Sample Circos plot (Krzywinski et al., 2009) of DNA (outer ring), RNA (middle ring) and protein (inner ring) data matching to chromosomes. (D) iPOP performed and integrated at multiple time points: T2, T3, T4 (viral-infected), T5 up to Tn states, including disease-state(s). Grey and green forms represent relative-healthy individual and a disease-state, respectively. (E) Report data back to genetic counsellor and medical practitioner with better informed choices for prevention and/or treatment (matched with pharmacogenetic data), if needed.
Figure 2
Figure 2. Highlights in iPOP
(A) Integration of DNA variants to assess disease risk (RiskGraph, top panel) and a sample pharmacogenome (bottom panel). Arrow heads point in the direction of the change in post-test probability (%). (B) Expression analysis (partial heatmap) of the transriptome and proteome over a time course spanning a respiratory syncytial viral (RSV) infection, with glucose monitoring (bottom, onset of T2D). Genes showing relative change in expression are clustered and represented as a network of inter- and intra-connected pathways: RNA (blue circle), protein (yellow square) and both RNA and protein (green hexagon). An example of a metabolite identified during the time course (inset panel).
Figure 3
Figure 3. Highlights in iPOP
(A) Sample phased DNA overlaid with RNA variant data corroborated with allelic specific expression (ASE) ratios for the ENDOD1 gene. Maternal transcript is expressed at 0.40, while the respective paternal transcript is expressed at 0.60. The triangle represents an indel in the paternally inherited transcript. (B) RNA editing in BLCAP (red arrows) result in protein level amino acid changes. BLCAP is found on the reverse strand (rev), and A→G editing appear as T→C. (C) An example of the diversity of isoforms observed in UQCR10 RNA and protein data. The two isoforms each contain the allelic specific variant A and G (rs76013375). Note isoform 2 spans into the intron position of DNA (faded); the true match is at the alternate spliced region located further downstream (not shown). RNA variant (A/G) results in amino acid change I:V, as identified in proteome mass spectrometric data (bottom). For (B) and (C), DNAnexus was used as a genome browser, where red nucleic acid represents mis-matches to reference genome (top). Blue and green nucleic acid strands represent forward and reverse Illumina reads, respectively.

Similar articles

  • Multiplex assay for multiomics advances in personalized-precision medicine.
    Popa ML, Albulescu R, Neagu M, Hinescu ME, Tanase C. Popa ML, et al. J Immunoassay Immunochem. 2019;40(1):3-25. doi: 10.1080/15321819.2018.1562940. Epub 2019 Jan 11. J Immunoassay Immunochem. 2019. PMID: 30632882 Review.
  • Promise of personalized omics to precision medicine.
    Chen R, Snyder M. Chen R, et al. Wiley Interdiscip Rev Syst Biol Med. 2013 Jan-Feb;5(1):73-82. doi: 10.1002/wsbm.1198. Epub 2012 Nov 26. Wiley Interdiscip Rev Syst Biol Med. 2013. PMID: 23184638 Free PMC article. Review.
  • Systems biology: personalized medicine for the future?
    Chen R, Snyder M. Chen R, et al. Curr Opin Pharmacol. 2012 Oct;12(5):623-8. doi: 10.1016/j.coph.2012.07.011. Epub 2012 Jul 31. Curr Opin Pharmacol. 2012. PMID: 22858243 Free PMC article. Review.
  • Integrative methods for analyzing big data in precision medicine.
    Gligorijević V, Malod-Dognin N, Pržulj N. Gligorijević V, et al. Proteomics. 2016 Mar;16(5):741-58. doi: 10.1002/pmic.201500396. Proteomics. 2016. PMID: 26677817 Review.
  • Personal omics profiling reveals dynamic molecular and medical phenotypes.
    Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HY, Chen R, Miriami E, Karczewski KJ, Hariharan M, Dewey FE, Cheng Y, Clark MJ, Im H, Habegger L, Balasubramanian S, O'Huallachain M, Dudley JT, Hillenmeyer S, Haraksingh R, Sharon D, Euskirchen G, Lacroute P, Bettinger K, Boyle AP, Kasowski M, Grubert F, Seki S, Garcia M, Whirl-Carrillo M, Gallardo M, Blasco MA, Greenberg PL, Snyder P, Klein TE, Altman RB, Butte AJ, Ashley EA, Gerstein M, Nadeau KC, Tang H, Snyder M. Chen R, et al. Cell. 2012 Mar 16;148(6):1293-307. doi: 10.1016/j.cell.2012.02.009. Cell. 2012. PMID: 22424236 Free PMC article.
See all similar articles

Cited by 20 articles

See all "Cited by" articles

LinkOut - more resources